KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Urology / 2019 / Cilt: 45 - Sayı: 1

Impact of metabolic syndrome on pre- and postoperative parameters in patients undergoing a HoLEP surgery

Tahsin Batuhan AYDOĞAN
Engin KAYA
EYMEN GAZEL
Serdar YALÇIN
Halil Çağrı AYBAL
Lütfi TUNÇ
Sayfa
98–103
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

A multivariateanalysis showed that the triglyceride level positively correlated with HT among Group 1 patients (p=0.03).Perioperative outcomes, such as enucleated tissue weight, efficiency of enucleation, enucleation rate, efficiency of morcellation, enucleation time, morcellation time, total operation time, total laser energy, and laserefficiency, were compared as non-significant between the two groups (p>0.05).Conclusion: We found that HoLEP can be considered a safe and effective surgical treatment for patientswith MS.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: We aimed to investigate the safety and success of the holmium laser enucleation of prostate(HoLEP) surgery in patients with metabolic syndrome (MS) versus those without MS who have similarprostate sizes.Material and methods: Data from 120 patients who underwent HoLEP by a single surgeon between November 2015 and January 2018 were prospectively analyzed.
📊
Temel Bulgular & Veri:Group 1 (n=40) and Group 2 (n=80) consistedof patients with and without MS, respectively.
💡
Sonuç & Katkı:A multivariateanalysis showed that the triglyceride level positively correlated with HT among Group 1 patients (p=0.03).Perioperative outcomes, such as enucleated tissue weight, efficiency of enucleation, enucleation rate, efficiency of morcellation, enucleation time, morcellation time, total operation time, total laser energy, and laserefficiency, were compared as non-significant between the two groups (p>0.05).Conclusion: We found that HoLEP can be considered a safe and effective surgical treatment for patientswith MS.
🔬Tür:Araştırma Makalesi
📍Kapsam:2015 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: We aimed to investigate the safety and success of the holmium laser enucleation of prostate(HoLEP) surgery in patients with metabolic syndrome (MS) versus those without MS who have similarprostate sizes.Material and methods: Data from 120 patients who underwent HoLEP by a single surgeon between November 2015 and January 2018 were prospectively analyzed. Group 1 (n=40) and Group 2 (n=80) consistedof patients with and without MS, respectively. Preoperative-and postoperative third month control variablesthat were compared between the groups included hemoglobin (Hb) level; International Prostate SymptomScore (IPSS); uroflowmetry parameters, such as maximum flow rate (Qmax) and average flow rate (Qave);post-voiding residue (PVR); voiding time (VT); and time to maximum flow rate (MVT).Results: For postoperative outcomes between the groups, only hospitalization time (HT) was significantamong IPSS, Qmax, Qave, PVR, VT, MVT, Hb decrease, and catheterization time (p=0.03). A multivariateanalysis showed that the triglyceride level positively correlated with HT among Group 1 patients (p=0.03).Perioperative outcomes, such as enucleated tissue weight, efficiency of enucleation, enucleation rate, efficiency of morcellation, enucleation time, morcellation time, total operation time, total laser energy, and laserefficiency, were compared as non-significant between the two groups (p>0.05).Conclusion: We found that HoLEP can be considered a safe and effective surgical treatment for patientswith MS.

🔖

Bu Makaleye Atıf Yap

AYDOĞAN, T. B., KAYA, E., GAZEL, E., YALÇIN, S., AYBAL, H. Ç., TUNÇ, L. (2019). Impact of metabolic syndrome on pre- and postoperative parameters in patients undergoing a HoLEP surgery. Turkish Journal of Urology, Cilt: 45 - Sayı: 1, 98–103. https://ajindex.com/articles/379824

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. Egan KB, The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. Urol Clin North Am 2016;43:289-97. [CrossRef] 2. Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, et al. EAU Guidelines on the Assessment of Nonneurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Eur Urol 2015;67:1099-109. [CrossRef] 3. Vincent MW, Gilling PJ. HoLEP has come of age. World J Urol 2015;33:487-93. [CrossRef] 4. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalance and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003;163:427-36. [CrossRef] 5. Park YW, Kim SB, Kwon H, Kang HC, Cho K, Lee Kl, et al. The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome. Urology 2013;82:674-9. [CrossRef] 6. Gacci M, Sebastianelli A, Salvi M, De Nunzio C, Tubaro A, Vignozzi L, et al. Central obesity is predictive of persistent storage lower urinary tract symptoms (LUTS) after surgery for benign prostatic enlargement: results of a multicentre prospective study. BJU Int 2015;116:271-7. [CrossRef] 7. Kwon T, Park S, Park S, Moon KH. Metabolic syndrome is predictive of lower urinary tract symptom improvement after holmium laser enucleation of the prostate for benign prostatic obstruction. Int Urol Nephrol 2017;49:1105-10. [CrossRef] 8. Ryl A, Rotter I, Slojewski M, Jedrzychowska A, Marcinowska Z, Grabowska M, et al. Can metabolic disorders in aging men contribute to prostatic hyperplasia eligible for transurethral resection of the prostate (TURP)? Int J Environ Res Public Health 2015;12:3327-42. [CrossRef] 9. Sener NC, Zengin K, Ozturk U, Bas O, Ercil H, Ekici M, et al. The impact of metabolic syndrome on the outcomes of transurethral resection of the prostate. J Endourol 2015;29:340-3. [CrossRef]